SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, has received a letter from the FDA indicating that it has successfully resolved all issues identified in an August 10, 2010, warning letter.   SNBL USA has systemically rebuilt the operation and re-established its preclinical drug development services, according to a company statement. Following the FDA’s September 2011 follow-up and general surveillance inspections, seven of the nine items were resolved. A report to finalize t...